Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. ASCO 2017 - du, Bois A; Vergote, I; Ferron, G (J Clin Oncol, 2017)
Abstr. 5501